Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) Total debt
Viatris Inc.'s total debt at the end of fiscal 2025 was $16.4B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $13.4B. Over the past ten years it has ranged from $7.4B (fiscal 2015) to $28.3B (fiscal 2020); the current reading is higher than 55% of that period. Viatris Inc. ranks 3rd of 86 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $16.4B | 2.77% |
| FY2024 | $16.0B | (11.83%) |
| FY2023 | $18.1B | (5.93%) |
| FY2022 | $19.3B | (16.52%) |
| FY2021 | $23.1B | (18.48%) |
| FY2020 | $28.3B | 106.98% |
| FY2019 | $13.7B | (1.30%) |
| FY2018 | $13.9B | (13.12%) |
| FY2017 | $16.0B | (5.57%) |
| FY2016 | $16.9B | 129.16% |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $13.4B | (6.92%) |
| Mar 2026 | $14.3B | (0.48%) |
| Dec 2025 | $14.4B | (11.37%) |
| Sep 2025 | $16.3B | (0.28%) |
| 42 more quarters | Free account |
Against its own ten years
Low $7.4B
High $28.3B
Ten-year median
$16.4B
Current reading's percentile
55
Total debt against peers
| Company | Total debt |
|---|---|
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.6B |
| VTRS Viatris Inc. | $13.4B |
| HLN Haleon PLC Sponsored ADR compare | $11.1B |
| ZTS Zoetis Inc. compare | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| HIMS Hims & Hers Health, Inc. compare | $1.4B |
| RDY Dr. Reddy's Laboratories Ltd compare | $760.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation compare | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement